

# How good are the outcomes of instrumented debulking operations for symptomatic spinal metastases and how long do they stand? A subgroup analysis in the Global Spine Tumour Study Group database.

## Authors names:

Bart Depreitere PhD<sup>1</sup>, Federico Ricciardi PhD<sup>2</sup>, Mark Arts MD<sup>3</sup>, Laurent Balabaud MD<sup>4</sup>, Cody Bunger MD<sup>5</sup>, Jacob M. Buchowski MD<sup>6</sup>, Chun Kee Chung PhD<sup>7</sup>, Maarten Hubert Coppes MD<sup>8</sup>, Michael George Fehlings MD<sup>9</sup>, Norio Kawahara MD<sup>10</sup>, Juan Antonio Martin-Benlloch MD<sup>11</sup>, Eric Maurice Massicotte MD<sup>9</sup>, Christian Mazel MD<sup>12</sup>, Bernhard Meyer, MD<sup>13</sup>, Fetullah Cumhur Oner MD<sup>14</sup>, Wilco Peul MD<sup>15</sup>, Nasir Quraishi FRCS<sup>16</sup>, Yasuaki Tokuhashi MD<sup>17</sup>, Katsuro Tomita MD<sup>18</sup>, Jorrit-Jan Verlaan MD<sup>14</sup>, Michael Wang MD<sup>19</sup>, Hugh Alan Crockard FRCS<sup>20</sup>, David Choi FRCS<sup>20</sup>

## Affiliations:

1. Division of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
2. Department of Statistical Science, University College London, London, United Kingdom
3. Department of Neurosurgery, Medical Center Haaglanden, Haaglanden, The Netherlands
4. Orthopaedics and Traumatology Centre, Clinique Mutualiste de la Porte de L'Orient, L'Orient, France
5. Department of Orthopedic Surgery, University Hospital of Aarhus, Aarhus, Denmark
6. Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
7. Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea
8. Department of Neurosurgery, University Medical Centre Groningen, Groningen, The Netherlands
9. Division of Neurosurgery and Spinal Program, University of Toronto and Toronto Western Hospital, Toronto, Canada
10. Department of Orthopedic Surgery, Kanazawa Medical University Hospital, Kanazawa, Japan
11. Spinal Unit, Hospital Universitario Dr Peset, Valencia, Spain
12. Department of Orthopedic surgery, L'Institut Mutualiste Montsouris, Paris, France
13. Department of Neurosurgery, Technische Universität München, Munich, Germany
14. Department of Orthopedic Surgery, University Medical Center Utrecht, The Netherlands
15. Department of Neurosurgery, Leiden University Medical Centre, Leiden, The Netherlands
16. Centre for Spine Studies and Surgery, Queens Medical Centre, Nottingham, UK
17. Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan
18. Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
19. Department of Neurosurgery, Jackson Memorial Hospital, University of Miami, Miami, USA
20. Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, University College London, London, United Kingdom

## Corresponding author

Bart Depreitere, Neurosurgery, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium; tel +32 16344290; fax +32 16344241

## **Abstract**

### **Background**

The benefits of surgery for symptomatic spinal metastases have been demonstrated, largely based on series of patients undergoing debulking and instrumentation operations. However, as cancer treatments improve and overall survival lengths increase, the incidence of recurrent spinal cord compression after debulking may increase. The aim of the current paper is to document the postoperative evolution of neurological function, pain and quality of life following debulking and instrumentation in the Global Spine Tumour Study Group (GSTSG) database.

### **Methods**

The GSTSG database is a prospective multicenter data repository of consecutive patients that underwent surgery for a symptomatic spinal metastasis. For the present analysis, patients were selected from the database that underwent decompressive debulking surgery with instrumentation. Preoperative tumor type, Tomita and Tokuhashi scores, EQ-5D, Frankel, Karnofsky, complications, survival, EQ-5D, Frankel, Karnofsky and Numeric Rating pain scores (NRS) at 3, 6, 12 and 24 months were analyzed.

### **Results**

914 patients underwent decompressive debulking surgery with instrumentation and had documented follow up until death or until 2 years post surgery. Median preoperative Karnofsky performance index was 70. 656 patients (71.8%) had visceral metastases and 490 (53.6%) had extraspinal bone metastases. Tomita scores were evenly distributed above (49.1%) and below or equal to 5 (50.9%), and Tokuhashi scores almost evenly distributed below or equal to 8 (46.3%) and above 8 (53.7%). Overall 12 month survival after surgery was 56.3%. The surgery resulted in EQ-5D health status improvement and NRS pain reduction, that was maintained throughout follow-up. Frankel scores improved at first follow-up in 25.0% of patients, but by 12 months neurological deterioration was observed in 18.8%.

### **Conclusion**

We found that palliative debulking and instrumentation surgeries were performed throughout all Tomita and Tokuhashi categories. These surgeries reduced pain scores and improved quality of life up to 2 years after surgery. After initial improvement, a proportion of patients experienced neurological deterioration by 1 year, but the majority of patients remained stable.

### **Keywords**

metastasis, spine, debulking surgery, quality of life, Frankel score

## Introduction

In the 1990s, regular use of spine stabilisation techniques following decompression or debulking surgery for spinal metastatic disease re-established the role for surgery. Previously, laminectomy alone resulted in inferior outcomes [8,23]. In a landmark randomized controlled trial, the combination of surgery and radiotherapy was demonstrated to produce significantly better neurological outcomes compared to radiotherapy alone for solid spinal metastases causing spinal cord compression [15], and reduction of pain and neurological improvement was seen in other studies [7,9,10,14,24]. In patients selected for surgery, operative management of spinal metastatic disease has been shown to improve and maintain quality of life, proportional to preoperative functional status [4,7]. In the latter prospective cohort study of 922 patients from the Global Spine Tumour Study Group (GSTSG), surgery included all techniques and approaches, ranging from percutaneous cementoplasty or pedicle screw fixation to treat instability from a pathological fracture, to less or more complete debulking surgery for decompression of the spinal cord (with or without instrumentation) to extralesional en bloc vertebrectomy. Despite the fact that surgery has been recognized as a useful option in the management of symptomatic spinal metastases, there is still little evidence to guide decision-making as to which subtype of surgery is most suitable or beneficial for a particular patient. The more aggressive operations are potentially associated with higher complication rates [20]. One would assume that less invasive options are usually chosen in situations that are 'more palliative', i.e. for patients with a perceived shorter life expectancy. Conversely, the more aggressive surgery subtypes might be advised when life expectancy is considered to be longer, and hence local tumor control is deemed necessary for longevity. However, to date, it is not clear whether techniques involving more radical tumour excision result in longer maintenance of neurological function or better survival. In addition, the long-term performance of the less invasive surgical options with respect to reduction of pain, maintenance of function, quality of life and survival, is not entirely clear. The question becomes more and more relevant in view of increasing survival lengths from improving cancer treatments.

The objective of our study was to review the outcome of decompressive debulking surgery with instrumentation in a prospective cohort of patients that underwent this surgery for a symptomatic spinal metastasis. Debulking and instrumentation followed by radiotherapy is amongst the most frequently used strategies to manage spinal metastases that cause spinal cord compression. We investigated the indications for such surgery, the patient-factors that might influence surgeons to choose this type of surgical option, and the outcomes of surgery. We hypothesized that these 'palliative' procedures successfully improved function, reduced pain and improved quality of life in the majority of patients with spinal metastases, but that we would see a deterioration over time in a subset of patients.

## Methods

The GSTSG database contains prospectively collected data of consecutive patients that were treated with surgery for symptomatic spinal metastatic disease in 20 specialist spine centers in Belgium, Canada, China, Denmark, France, Germany, Japan, The Netherlands, Spain, South Korea, the United Kingdom, and the United States of America. Patients were excluded if they were younger than 18 years or if they were unable to give informed consent. Data were anonymized and entered in the database by the spine surgeon and their team. The data were kept on secure servers managed by an established data-management company (Applied Network Solutions, Basingstoke, UK) with full secure socket layer certificated encryption software. Data forms were locked at four weeks following data entry in order to preclude subsequent changes. Local institutional ethical approval was granted for all centres according to national regulations. Patients for this study were recruited between January 1<sup>st</sup> 2004 and September 1<sup>st</sup> 2016 and gave informed consent for data collection, analysis and publication.

Collected data includes preoperative tumor type, Tomita score [19], Tokuhashi score [18], pain numeric rating score (NRS), Frankel score, EQ-5D-3L quality of life index, Karnofsky Performance Status score (KPS), type of surgery [3], complications, and postoperative pain visual analogue score, Frankel score, EQ-5D-3L quality of life index, KPS at each follow up (3 months, 6 months, 1 year, 2 years), as well as date of death. For the current analysis, we specifically looked at the group of patients that underwent partial removal of less than 50% of the tumor in combination with instrumented stabilization of the spine and analyzed the above variables. Patient that underwent piecemeal near complete, piecemeal complete or en bloc excisions, and patients with missing data on the exact surgical procedure, were excluded. Also, patients with follow up less than 2 years and without documented date of death, were excluded from the analysis.

Data were analyzed in a descriptive way using summary statistics: means and standard deviations or medians and interquartile ranges for continuous variables depending on their distribution, and proportions for binary and categorical variables. Survival data were analyzed using Kaplan-Meier statistics and Cox regression analysis. Statistical analyses were performed in Stata 14 (College Station, Texas, USA). P-values below 0.05 were considered significant.

## Results

914 patients underwent a decompressive debulking (i.e. partial removal < 50 % of the tumor as determined by the operating surgeon) with instrumentation and had documented follow up until death or until 2 years post surgery. Mean age was 60.7 years (SD 12.3 years). 500 patients (54.7%) were males. Data on the entire GSTSG dataset, including full demographic data, is available in Choi D et al [4].

Median preoperative KPS was 70 (IQR 50-80) and 32.3% of patients were admitted with a KPS  $\geq$ 80. Mean EQ-5D index was 0.37 (SD  $\pm$ 0.30), and median NRS was 7 (IQR 4-8). 383 patients were neurologically intact upon admission (41.9%), 299 had Frankel score D (32.7%), 223 had Frankel scores A, B or C (24.4%), and 9 were not documented (1.0%). With respect to primary tumours, the most frequent tumour types were breast carcinoma (167 patients, 18.3%) and lung carcinoma (133 patients, 14.6%). Visceral metastases were present in 656 patients (71.8%), and extraspinal bone metastases in 490 patients (53.6%). Tomita scores were evenly distributed above (49.1%) and below or equal to 5 (50.9%). Similarly, Tokuhashi scores were almost evenly distributed below or equal to 8 (46.3%) and above 8 (53.7%) (Table 1). Tomita score of 5 or higher, or Tokuhashi score of 8 or below were considered thresholds beyond which the original publications recommended palliative surgery only [18,19].

The number of levels instrumented was 1 to 3 in 187 patients (20.5%), 4 to 6 levels in 489 patients (53.5%) and 7 or more levels in 104 patients (11.4%), with missing data in 134 (14.7%). The incidence of intraoperative and postoperative complications is shown in table 2. The most frequent complications were wound complications, with a rate of 4.6%. 30-day mortality was 3.8%. 6-month survival was 71.2%, 12-month survival 56.3% and 24-month survival 32.5% (Figure 1).

Debulking surgery with instrumentation in general resulted in substantial EQ-5D health status improvement, that was maintained above 0.70 throughout follow-up (Figure 2). Pain intensity was reduced and the reduction was maintained over 24 months with a stable median NRS of 2 (Figure 3). KPS scores started from a median of 70 preoperatively and slightly increased postoperatively (Figure 4).

Frankel scores were improved at first follow-up in 106 out of 423 patients (25.0%). At 6 months, patients with Frankel A-C were reduced to less than 1% (Figure 5), partially explained by patients further improving (14.9% between 3 and 6 months) and by a proportion of patients dying. At 12

months, however, an increase in patients with Frankel A-C was observed, due to a proportion of patients of 18.8% that deteriorated between 6 and 12 months (Figure 6).

## **Discussion**

In the present retrospective analysis of prospectively collected data from the GSTSG, we specifically focused on the patients that underwent debulking surgery with the addition of instrumentation for reconstruction, in a consecutive cohort of 914 patients. In the consensus statement of the GSTSG, in which surgery types for spinal metastases were classified into 5 categories [3], this surgery falls under category 2, i.e. palliative debulking. We found that these procedures were able to produce an improvement in health status and a reduction of pain that was maintained throughout follow-up to two years or death. Palliative debulking surgery was able to improve the Frankel scores at first follow-up in a quarter of patients. A subsequent worsening of the neurological status was observed between 6 and 12 months in 18.8% of patients. The complication rate was acceptable, with intraoperative complications in less than 2% and overall postoperative complications in up to 22.2%. The overall 1 year survival was 56.3%.

The Tomita and Tokuhashi prognostic scores have been proposed as guides to decide when palliative surgery should be performed, based on predicted prognosis. Tomita et al. advocated to perform en bloc or complete excisions in patients with a Tomita score between 2 and 5, palliative surgeries in patients with a 6-7 score and conservative supportive care in higher scores [19]. Surprisingly, in our present cohort, palliative surgeries were performed throughout all Tomita and Tokuhashi categories. Surgeons did not appear to choose palliative operations based on overall metastatic disease load or prognostic scoring systems. Although this may reflect a certain degree of pragmatism in surgeons' decision making, it is more likely that it particularly reflects that the available scoring systems are not sufficiently accurate in their prediction of survival to support decision-making in individual patients. It has been found by Choi et al in a GSTSG analysis that none of the predictive scoring systems had good predictive value [5].

In previous GSTSG publications a strong overall association between pre-operative KPS and subsequent survival has been demonstrated [4,20]. Although this association to some extent may reflect an effect of treatment decisions, also in multivariate analyses KPS was an independent predictor of survival, suggesting that to some extent KPS may be a good clinical guide. In order to further help personalized management, the GSTSG developed a risk calculation tool based on a prediction model build on its

database, that visualizes the patient's expected survival in relation to the average survival of patients with spinal metastases [6].

Several small to medium size series in the literature report on palliative surgery for symptomatic spinal metastases with outcomes comparable to our series. Bouras et al looked at 88 patients that underwent decompression/debulking with or without fixation and that had a Tokuhashi score  $\leq 8$  [2]. 55.3% of their patients improved, with reduced pain and restored or maintained ambulation without severe complications at 2 months. The rate of intraoperative complications was 4.5% and 23.9% for postoperative complications, which is similar to our findings. Ha et al studied 43 patients that underwent either posterior decompression and fusion or a combined anterior-posterior reconstruction [8]. 20.9% experienced Frankel score improvement at 3 months, and 12 month survival was 31.5% in the posterior only group and 38.7% in the anteroposterior group. In a systematic review of palliative decompressive surgeries, it was found that there was no difference in immediate outcome between anterior and posterior techniques, nor between open and minimally invasive techniques [1]. In the prospective multicenter AOSpine study, which included 142 patients and of whom 94.4% underwent instrumentation surgery, the proportion of patients who were able to walk four steps independently postoperatively was higher than the preoperative proportion at all follow up times up to 12 months. 29.6% of patients experienced a complication within 30 days, 3 month mortality was 28.2% and 12 month mortality 62.0% [7]. Longer follow up was available in the study of North et al, who modeled ability to walk in a series of 61 patients that underwent palliative surgery for spinal metastases [14]. Twelve patients lost the ability to walk postoperatively over the course of 1.6 years. To the best of our knowledge, the present study is the only analysis on palliative surgeries with the current order of sample size that looked at clinical outcome over 2 years.

The exact role of the more aggressive surgeries for spinal metastases is subject to debate. It has become clear from Tomita's and others' series that en bloc excisions do not preclude recurrence, [13,16,19]. Since time to recurrence in these series of solitary thyroid, renal cell carcinoma or breast metastases was up to 8 years, it seems that the value of the more aggressive surgeries in the context of metastatic disease lies in buying time. Our study of debulking surgeries shows that clinical improvements were achieved for a reasonable duration, but with a 18.8% of patients experiencing neurological deterioration by one year. Although this could theoretically have been caused by newly developed different spinal metastases, this figure is in agreement with reported rates of symptomatic loss of local control of 20% [11] and 22% [21] at 1 year in smaller series. Hence, based on the present data, a choice for debulking comes with risk of approximately one fifth that the patient may suffer recurrent spinal cord compression if he/she survives for more than one year. From the perspective of

the many unknown variables during the course of cancer, this choice seems very justifiable to date. As medical treatments and survival continue to improve over the years, also radiotherapy techniques have advanced. The advent of spinal stereotactic radiosurgery has led to changing management philosophies, with the focus being more on early surgery for maintaining stability and on radiotherapy/radiosurgery for local control of the spinal metastasis, and less reliance on debulking surgery. In the NOMS algorithm, separation surgery – i.e. debulking to create a tumour-free margin surrounding the spinal cord – is only advocated when the tumour extends to the epidural space or causes spinal cord compression and the tumour histology is not or intermediately radioresponsive [17]. However, it is still too early to fully assess the merits of this newer strategy. In an outcome study by Laufer et al. on 186 patients in whom separation surgery and spinal radiosurgery was used, the authors reported that 18.3% of patients had local progression on imaging at a median of 4.8 months, 55.4% died at a median of 5.6 months and 26.3% were alive and without progression at a median of 7.1 months [12]. Although the GSTSG database includes patients from centers that have adopted the NOMS principles, it is of note that the results in terms of survival of our current study – that also includes debulkings more extensive than separation - are better than those reported by Laufer et al.

Limitations of our current study relate to the standardized data collection inherent to prospective databases, that may not capture the subtleties of the rationale for certain management decisions and all associated variables. This includes surgeons' preferences and centers' philosophies as to which procedure to select in which exact situation. In addition, the classification of 'debulking' as less than 50% of the tumor being removed, was based on an estimation of the surgeon and not on a comparison of pre- and postoperative imaging. We do not expect, however, that the rough nature of this estimation has had a real influence on the results of the current analysis. Also, although data capture was prospective, some bias may result from incomplete entries or missing data. Since patients were recruited to the GSTSG database after referral for spinal surgery, there may be a bias towards patients who are perceived by referring oncologists as potentially having a better prognosis. Also, the beneficial effects of systemic therapies and radiotherapy on patient outcomes in terms of performance and survival cannot be isolated. Although the majority of patients received pre- or postoperative radiotherapy for the spinal metastasis, there were too many missing data on timing, type and dose of radiotherapy to enable the inclusion of radiotherapy outcomes in our analysis.

Nevertheless, the GSTSG database represents the largest prospective database on patients with spinal metastases managed surgically that includes systematic capture of quality of life, pain, functional and neurological outcomes. Based on the current analysis of 914 patients that underwent debulking and instrumentation surgery for symptomatic spinal metastases, we strongly recommend the



consideration of this type of surgery for patients in whom estimated survival is deemed sufficiently long to benefit from decreased pain, improved or maintained neurological function and improved quality of life. However, patients should be counseled that this is associated with a risk of approximately one fifth of recurrent spinal cord compression if he/she survives for more than one year. In view of improving cancer treatments and longer survivals, this is a relevant observation. It is unsure how this should be dealt with, and an important clue may be in improved survival prediction and customized strategies.

## **Conclusion**

In a prospective cohort of debulking and instrumentation surgeries for symptomatic spinal metastases taken from the GSTSG database, we found that these surgeries were safe and were able to produce and maintain reduction in pain and improvement in quality of life for at least two years after surgery. Frankel neurological status improved after surgery in one quarter of patients, but a fifth of patients experienced neurological deterioration by 1 year. Palliative procedures offer benefits to patients with symptomatic spinal metastases and have an important place in treatment algorithms.

## **Funding**

This work was funded by the Global Spine Tumour Study Group, a registered charity of England and Wales, Charity Commission number 1134934, and DePuy Synthes (Johnson and Johnson). This study was performed in part at University College London Biomedical Research Centre, which receives funding from the National Institute for Health Research, UK. The sponsors had no role in the design or conduct of this research.

## **Conflict of interest**

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

## **Ethical approval**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the local institutional research committees according to national regulations and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

## **Informed consent**

Informed consent was obtained from all individual participants included in the study.

## **References**

1. Bakar D, Tanenbaum JE, Phan K, Alentado VJ, Steinmetz M, Benzel EC, Mroz TE (2016) Decompression surgery for spinal metastases: a systematic review. *Neurosurg Focus* 41: E2
2. Boura T, Zairi F, Arikat A, Vieillard mH, Allaoui M, Assaker R (2018) Decision making for the surgical treatment of vertebral metastases among patients with short predicted survival. *World Neurosurg* 111: e573-e580
3. Choi D, Crockard A, Bungler C et al (2010) Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group. *Eur Spine J* 19: 215-222
4. Choi D, Fox Z, Albert T, Arts M, Balabaud L, Bungler C, Buchowski JM, Coppes MH, Depreitere B, Fehlings MG, Harrop J, Kawahara N, Martin-Benlloch JA, Massicotte EM, Mazel C, Oner FC, Peul W, Quraishi N, Tokuhashi Y, Tomita K, Verlaan JJ, Wang M, Crockard HA (2015) Prediction of Quality of Life and Survival After Surgery for Symptomatic Spinal Metastases: A Multicenter Cohort Study to Determine Suitability for Surgical Treatment. *Neurosurgery* 77: 698-708; discussion 708
5. Choi D, Ricciardi F, Arts M, Buchowski JM, Bungler C, Chung CK, Coppes M, Depreitere B, Fehlings M, Kawahara N, Leung Y, Martin-Benlloch A, Massicotte E, Mazel C, Meyer B, Oner C, Peul W, Quraishi N, Tokuhashi Y, Tomita K, Ulbricht C, Verlaan JJ, Wang M, Crockard A (2018) Prediction accuracy of common prognostic scoring systems for metastatic spine disease: results of a prospective international multicentre study of 1469 patients. *Spine* 43: 1678-1684
6. Choi D, Pavlou M, Omar R, Arts M, Balabaud L, Buchowski JM, Bungler C, Chung CK, Coppes MH, Depreitere B, Fehlings MG, Kawahara N, Lee CS, Leung Y, Martin-Benlloch JA, Massicotte EM, Mazel C, Meyer B, Oner FC, Peul W, Quraishi N, Tokuhashi Y, Tomita K, Ulbricht C, Verlaan JJ, Wang M, Crockard HA. A novel risk calculator to predict outcome after surgery for symptomatic spinal metastases; use of a large prospective patient database to personalise surgical management (2019) *Eur J Cancer* 107:28-36

7. Fehlings MG, Nater A, Tetreault L, Kopjar B, Arnold P, Dekutoski M, Finkelstein J, Fisher C, France J, Gokaslan Z, Massicotte E, Rhines L, Rose P, Sahgal A, Schuster J, Vaccaro A (2016) Survival and Clinical Outcomes in Surgically Treated Patients With Metastatic Epidural Spinal Cord Compression: Results of the Prospective Multicenter AOSpine Study. *J Clin Oncol* 34: 268-276
8. Gilbert RW, Kim JH, Posner JB (1978) Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. *Ann Neurol* 3: 40-51
9. Ha KY, Kim YH, Ahn JH, Park HY (2015) Factors affecting survival in patients undergoing palliative spine surgery for metastatic lung and hepatocellular cancer: does the type of surgery influence the surgical results for metastatic spine disease? *Clin Orthop Surg* 7: 344-350
10. Ibrahim A, Crockard A, Antonietti P, Boriani S, Bünger C, Gasbarrini A, Grejs A, Harms J, Kawahara N, Mazel C, Melcher R, Tomita K (2008) Does spinal surgery improve the quality of life for those with extradural (spinal) osseous metastases? An international multicenter prospective observational study of 223 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2007. *J Neurosurg Spine* 8: 271-8
11. Jansson KA, Bauer HCF (2006) Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases. *Eur Spine J* 15: 196-202
12. Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, Cox BW, Yamada Y, Bilsky MH. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients (2013) *J Neurosurg Spine* 18:207-214
13. Matsumoto M, Tsuji T, Iwanami A, Watanabe K, Hosogane N, Ishii K, Nakamura M, Morioka H, Toyama Y (2013) Total en bloc spondylectomy for spinal metastasis of differentiated thyroid cancers: a long-term follow-up. *J Spinal Disord Tech* 26: E137-142
14. North RB, LaRocca VR, Schwartz J, North CA, Zahurak M, Davis RF, McAfee PC (2005) Surgical management of spinal metastases: analysis of prognostic factors during a 10-year experience. *J Neurosurg Spine*. 2: 564-73
15. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet* 366: 643-648

16. Sakauro H, Hosono N, Mukai Y, Ishii T, Yonenobu K, Yoshikawa H (2004) Outcome of total en bloc spondylectomy for solitary metastasis of the thoracolumbar spine. *J Spinal Disord Tech* 17: 297-300
17. Spratt DE, Beeler WH, de Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, Shultz DB, Smith SR, Berlin A, Dahele M, Slotman BJ, Younge KC, Bilsky M, Park P, Szerlip NJ. An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. (2017) *Lancet Oncol* 18:e720-e730
18. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J (2005) A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. *Spine* 30: 2186-2191
19. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T (2001) Surgical strategy for spinal metastases. *Spine* 26: 298-306
20. Verlaan JJ, Choi D, Versteeg A, Albert T, Arts M, Balabaud L, Bungler C, Buchowski JM, Chung CK, Coppes MH, Crockard HA, Depreitere B, Fehlings MG, Harrop J, Kawahara N, Kim ES, Lee CS, Leung Y, Liu Z, Martin-Benlloch A, Massicotte EM, Mazel C, Meyer B, Peul W, Quraishi NA, Tokuhashi Y, Tomita K, Ulbricht C, Wang M, Oner FC (2016) Characteristics of Patients Who Survived < 3 Months or > 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection? *J Clin Oncol* 34: 3054-3061
21. Weigel B, Maghsudi M, Neumann C, Kretschmer R, Müller FJ, Nerlich M (1999) Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. *Spine* 24: 2240-6
22. Yokogawa N, Murakami H, Demura S, Kato S, Yoshioka K, Hayashi H, Ishii T, Igarashi T, Fang X, Tsuchiya H (2014) Perioperative complications of total en bloc spondylectomy: adverse effects of preoperative irradiation. *PLOS One* 9: e98797
23. Young RF, Post EM, King GA (1980) Randomized prospective comparison of laminectomy and radiotherapy. *J Neurosurg* 53: 741-748
24. Zairi F, Vieillard MH, Devos P, Rabih A, Gras L, Assaker R (2015) Management of neoplastic spinal tumors in a spine surgery care unit. *Clin Neurol Neurosurg* 128: 35-40

Figures




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

**Figure legends**

Figure 1. Kaplan-Meier survival curve (n=914).

Figure 2. Evolution of EQ-5D health status over time (mean values  $\pm$  standard deviation)(preop n=765, 3m n=426, 6m n=293, 12m n=218, 24m n=122).

Figure 3. Evolution of Numeric Rating Score pain intensity over time (median values, IQR)(preop n=776, 3m n=427, 6m n=291, 12m n=213, 24m n=117).

Figure 4. Evolution of Karnofsky Performance Status scores over time (median values, IQR)(preop n=902, 3m n=415, 6m n=360, 12m n=209, 24m n=116).

Figure 5. Preoperative and postoperative Frankel scores expressed in percentage of patients in each follow up moment (preop n=905, 3m n=423, 6m n=262, 12m n=179, 24m n=104).

Figure 6. Proportion of patients experiencing Frankel score worsening from one follow up moment to the next versus proportion of patients improving or being stable in the non-instrumented and instrumented groups (3m n=423, 6m n=262, 12m n=179, 24m n=104).